News
3 High-Yield Stocks Still Worth Buying
Who doesn't like free money? While they may be somewhat forgotten as the stock market hits seemingly one new high after another, high-yield dividend stocks play an important role in providing....
This Possible Dog of the Dow Just Got Even More Interesting
If you invest in the Dogs of the Dow every year, you could end up buying Pfizer (NYSE: PFE) on Jan. 1. The strategy calls for buying the top 10 highest dividend-yielding stocks in the Dow Jones....
How Safe Is Medtronic's Dividend?
Advances in medicine have come at a fast and furious pace in recent decades. New pharmaceuticals and biotechnology solutions have made patients healthier, and medical devices like the ones that....
The Top 3 Dividend Aristocrats to Watch in 2018
Income investors rely on the Dividend Aristocrats to provide them with reliable, growing dividend income. These stocks have all raised the amount they pay in dividends year in and year out for at....
Why 2017 Was a Year to Remember for Johnson & Johnson
With less than two weeks remaining in 2017, Johnson & Johnson (NYSE: JNJ) is on track to have its second-best year of the century so far for stock performance. The healthcare giant's share....
The 5 Best-Selling Drugs of 2017
We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.Payers and patients across the....
3 Top Dividend Aristocrats to Buy for 2018
It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends....
Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?Actually, it's two: Johnson & Johnson....
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm....
Why Teva Pharmaceutical Is Soaring 13.5% Today
After providing investors with the details of its latest cost-savings plan, including a massive workforce reduction, Teva Pharmaceutical (NYSE: TEVA) shares are rallying 13.5% as of 1 p.m. EST....
Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors
Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant....
AbbVie Makes Progress on Quest to Diversify
AbbVie's (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide....
These 3 Stocks Just Raised Their Dividends
We're getting down to the wire now, with only a few short weeks until the close of 2017. It was a year nearly full to the brim with dividend raises, so income investors will be sorry to see it....
3 Dividend Stocks to Buy on Sale
Stocks that pay out the highest dividend yields aren't always the best ones to buy. Sometimes, the yields are artificially high in advance of a big dividend cut. And sometimes the dividend is....
Why Seattle Genetics, Inc. Fell Today
Seattle Genetics (NASDAQ: SGEN) is down 5.9% as of this writing, having been down as much as 10.5% Friday following a weekend of presentations at the American Society of Hematology (ASH)....
Better Buy: Illumina, Inc. vs. Pacific Biosciences
Rapid advances in the ability to quickly and cheaply sequence DNA and RNA are fueling research in cancer, immunology, complex diseases, forensics, agriculture, and many other areas, while clinical....
3 High-Yield Dividend Stocks to Buy in 2018
Dividend investors on the hunt for above average income opportunities may want to place a heavy emphasis on pharmaceutical stocks next year. Despite the political turmoil surrounding the....
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
Shares of the clinical-stage biotech bluebird bio (NASDAQ: BLUE) rose by as much as 23.9% in pre-market trading today. The catalyst? The company reported that its CAR-T candidate, bb2121, produced....
You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed
For years, chemotherapy was the best treatment that the world of medicine had to offer in fighting cancer. That's no longer true. A powerful new class of cancer drugs called immunotherapies has....
Is Gilead Sciences, Inc. a Buy?
With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. After getting off to a rocky....